ALKS vs. CRL
ALKS (Alkermes plc) and CRL (Charles River Laboratories International, Inc.) are both stocks. Both are in the Healthcare sector — ALKS in Biotechnology, CRL in Diagnostics & Research. Over the past 10 years, ALKS returned 0.53%/yr vs 8.34%/yr for CRL. At a 0.36 correlation, their price movements are largely independent.
Performance
ALKS vs. CRL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALKS achieves a 58.26% return, which is significantly higher than CRL's -6.00% return. Over the past 10 years, ALKS has underperformed CRL with an annualized return of 0.53%, while CRL has yielded a comparatively higher 8.34% annualized return.
ALKS
- 1D
- -1.42%
- 1M
- 13.80%
- YTD
- 58.26%
- 6M
- 55.37%
- 1Y
- 43.86%
- 3Y*
- 12.04%
- 5Y*
- 12.09%
- 10Y*
- 0.53%
CRL
- 1D
- -0.29%
- 1M
- 15.14%
- YTD
- -6.00%
- 6M
- -2.86%
- 1Y
- 23.45%
- 3Y*
- -3.40%
- 5Y*
- -11.84%
- 10Y*
- 8.34%
ALKS vs. CRL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ALKS Alkermes plc | 58.26% | -2.71% | 3.68% | 6.16% | 12.34% | 16.59% | -2.21% | -30.87% | -46.08% | -1.53% |
CRL Charles River Laboratories International, Inc. | -6.00% | 8.06% | -21.91% | 8.49% | -42.17% | 50.80% | 63.56% | 34.97% | 3.41% | 43.65% |
Correlation
The correlation between ALKS and CRL is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Jun 23, 2000 | 0.36 |
Fundamentals
ALKS:
$7.36B
CRL:
$9.18B
ALKS:
$0.91
CRL:
-$3.75
ALKS:
4.76
CRL:
2.29
ALKS:
4.20
CRL:
3.12
ALKS:
$1.56B
CRL:
$4.03B
ALKS:
$1.02B
CRL:
$1.00B
ALKS:
$249.70M
CRL:
$737.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALKS vs. CRL — Risk / Return Rank
ALKS
CRL
ALKS vs. CRL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Alkermes plc (ALKS) and Charles River Laboratories International, Inc. (CRL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALKS | CRL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.56 | ||
| Sortino ratioReturn per unit of downside risk | +0.77 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.13 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 1.99 | 0.70 | +1.29 |
| Martin ratioReturn relative to average drawdown | 4.60 | 1.42 | +3.18 |
Loading charts...
Drawdowns
ALKS vs. CRL - Drawdown Comparison
The maximum ALKS drawdown since its inception was -96.14%, which is greater than CRL's maximum drawdown of -78.23%. Use the drawdown chart below to compare losses from any high point for ALKS and CRL.
Loading charts...
Drawdown Indicators
| ALKS | CRL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.14% | -78.23% | -17.91% |
Max Drawdown (1Y)Largest decline over 1 year | -22.20% | -33.88% | +11.68% |
Max Drawdown (3Y)Largest decline over 3 years | -31.58% | -63.52% | +31.94% |
Max Drawdown (5Y)Largest decline over 5 years | -33.18% | -78.23% | +45.05% |
Max Drawdown (10Y)Largest decline over 10 years | -80.58% | -78.23% | -2.35% |
Current DrawdownCurrent decline from peak | -54.84% | -59.09% | +4.25% |
Average DrawdownAverage peak-to-trough decline | -67.23% | -25.75% | -41.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.81% | 16.50% | -6.69% |
Volatility
ALKS vs. CRL - Volatility Comparison
The current volatility for Alkermes plc (ALKS) is 10.63%, while Charles River Laboratories International, Inc. (CRL) has a volatility of 15.13%. This indicates that ALKS experiences smaller price fluctuations and is considered to be less risky than CRL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALKS | CRL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.63% | 15.13% | -4.50% |
Volatility (6M)Calculated over the trailing 6-month period | 30.32% | 34.64% | -4.32% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.87% | 44.96% | -4.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 37.32% | 42.74% | -5.42% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.29% | 37.77% | +3.52% |
Dividends
ALKS vs. CRL - Dividend Comparison
Neither ALKS nor CRL has paid dividends to shareholders.
Financials
ALKS vs. CRL - Financials Comparison
This section allows you to compare key financial metrics between Alkermes plc and Charles River Laboratories International, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ALKS vs. CRL - Profitability Comparison
ALKS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported a gross profit of 0.00 and revenue of 392.91M. Therefore, the gross margin over that period was 0.0%.
CRL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported a gross profit of 0.00 and revenue of 995.83M. Therefore, the gross margin over that period was 0.0%.
ALKS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported an operating income of -48.28M and revenue of 392.91M, resulting in an operating margin of -12.3%.
CRL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported an operating income of 119.90M and revenue of 995.83M, resulting in an operating margin of 12.0%.
ALKS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported a net income of -66.48M and revenue of 392.91M, resulting in a net margin of -16.9%.
CRL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported a net income of -14.84M and revenue of 995.83M, resulting in a net margin of -1.5%.
Frequently Asked Questions
ALKS and CRL have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRL has higher volatility (15.13%) compared to ALKS (10.63%). In terms of maximum drawdown, ALKS dropped -96.14% vs CRL's -78.23%.
ALKS currently has the higher Sharpe Ratio (1.08 vs 0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALKS and CRL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer